Medline Stock Plummets 12% Amid FDA Scrutiny and Securities Law Probe

Key Facts

1Medline is under legal investigation for potential securities law violations following an FDA warning regarding manufacturing practice violations.

2The company lowered its full-year adjusted EBITDA guidance despite beating second-quarter earnings and revenue estimates.

3Medline's stock price dropped over 12% on August 5, 2026, following the release of its Q2 results and lowered guidance.

In a move reflecting heightened operational and legal challenges in the healthcare sector, Medline Inc. is facing dual pressure following an FDA warning regarding manufacturing practice violations. According to reports, the company is also under a legal investigation for potential federal securities law violations. This combination of regulatory and legal scrutiny triggered a sharp decline in the stock price, which dropped over 12% on August 5, 2026.

Despite beating second-quarter earnings and revenue estimates, Medline lowered its full-year adjusted EBITDA guidance, signaling concerns over future profitability. This downward revision led analysts at Stifel Nicolaus to cut their price target for the stock to $45. The FDA warning specifically cited failures in investigating batch discrepancies, marking the second regulatory action against the company's quality standards within a two-month period.

Per market data, MDLN was priced at $35.23 at the close of August 7, 2026, having traded between a day low of $34.03 and a high of $35.81. Looking ahead, while the economic calendar shows German Factory Orders on August 6, 2026, as a broader manufacturing catalyst, investors remain focused on further updates regarding the ongoing legal probe and the company's regulatory compliance status.

Sources:

Financial Modeling Prep